# Accelerated vs. Standard Continuous Renal Replacement Therapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator

Study · id `cardio:ct-nct06696235` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06696235](<https://clinicaltrials.gov/study/NCT06696235>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06696235

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 408 participants.

## Technical summary

Registry record NCT06696235. Randomized; no masking; primary purpose treatment. Start 2024-12-31 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 408 participants (planned count; ClinicalTrials.gov record NCT06696235, source copy `cardio:ctgov-nct06696235-2026-01-05`, retrieved 2026-10-31)
- Started: 2024-12-31 (actual) (ClinicalTrials.gov record NCT06696235, source copy `cardio:ctgov-nct06696235-2026-01-05`, retrieved 2026-10-31)
- Primary completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT06696235, source copy `cardio:ctgov-nct06696235-2026-01-05`, retrieved 2026-10-31)
- Completion: 2029-06-30 (anticipated) (ClinicalTrials.gov record NCT06696235, source copy `cardio:ctgov-nct06696235-2026-01-05`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT06696235, source copy `cardio:ctgov-nct06696235-2026-01-05`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06696235-2026-01-05`, retrieved 2026-10-31)

## The registry's words

- Brief title: Accelerated vs. Standard Continuous Renal Replacement Therapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator
- Acronym: REDUCE-ECMO
- Condition: Cardiogenic Shock
- Condition: Acute Kidney Injury
- Intervention (Device): Early initiation of continuous renal replacement therapy
- Intervention (Device): Standard initiation of continuous renal replacement therapy
- Lead sponsor: Samsung Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Registry lists this organization as the lead sponsor: Samsung Medical Center (`cardio:org-samsung-medical-center`)

## Provenance

Content hash: 5d4cec9f52bf62eafc5027aa100ee491f4a0bc4f57f8e6f66d9652527cad1214
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
